GET DAILY SIGNALSOnKure Therapeutics (OKUR) Stock Climbs +22% Over 30 Days on Pipeline Progress
Key Takeaways
- OKUR shares rebounded roughly 22% over the last 30 days, rising from about $2.35 to $2.87 as the stock recovered from its October low.
- The move follows OnKure's third-quarter 2026 results, which showed a narrower-than-expected net loss per share.
- Despite the short-term rebound, the stock remains down roughly 31% over the last quarter after sliding to a 52-week low near $2.01 in mid-October.
- Sentiment has been shaped by the company's strategic pivot toward next-generation PI3Kα pan-mutant-selective inhibitors, including OKI-345 and OKI-355.
- Analyst price targets were reset lower in recent quarters, with coverage still skewed to Buy or Outperform ratings despite the revisions.
OnKure Therapeutics (OKUR) Company Background
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Boulder, Colorado. The company discovers and develops precision medicines that target biologically validated drivers of cancers and vascular anomalies. Its research platform uses structure-based and computational chemistry to design highly selective small-molecule drug candidates aimed at improving clinical outcomes while reducing off-target toxicity.
The company's lead clinical asset is OKI-219, a mutant-selective PI3Kα H1047R inhibitor evaluated in the Phase 1 PIKture-01 trial in advanced solid tumors, including breast cancer. OnKure has increasingly emphasized its next-generation PI3Kα pan-mutant-selective pipeline, led by OKI-345 in breast cancer and OKI-355 in vascular anomalies, with investigational new drug (IND) submissions planned for the first half of 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors follow OKUR primarily for progress on these clinical programs, data readouts, and the company's cash runway.
OKUR Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, OKUR climbed approximately 22%, from a closing price near $2.35 to about $2.87. The recovery accelerated in late October and early November, with a particularly sharp single-session gain in early November that lifted the shares more than 13% in one trading day.
The longer-term picture is more mixed. Over the last quarter, the stock fell roughly 31%, declining from around $4.14 in early August to its current level. The shares reached a 52-week low near $2.01 in mid-October before the recent rebound. This divergence highlights how the recent 30-day advance represents a partial recovery from a deeper multi-month drawdown rather than a new high.
Factors Behind the Recent 30-Day Gain
The 30-day advance was driven by a combination of a technical rebound from oversold levels and renewed investor attention around OnKure's pipeline. After touching a 52-week low in mid-October, the shares found support as selling pressure eased and buyers returned to the clinical-stage name.
The company's third-quarter 2026 financial results, reported in early November, provided a catalyst. OnKure posted a net loss per share that was narrower than consensus estimates, and management highlighted continued progress advancing its next-generation PI3Kα pan-mutant-selective candidates, including OKI-355 in vascular anomalies and OKI-345 in breast cancer. The company also announced PANORAMA, an OnKure-sponsored registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies.
Analyst activity was mixed but remained generally constructive. Oppenheimer maintained an Outperform rating while lowering its price target to $14 from $30, and H.C. Wainwright kept a Buy rating while reducing its target to $21 from $27. The revisions reflected recalibrated expectations around the company's shifting development priorities rather than a withdrawal of coverage, and the shares still responded positively to the quarterly update.
Drivers of the Quarterly Decline
The quarterly decline of roughly 31% reflects a broader repricing of OnKure's near-term development strategy. Earlier in 2026, the company signaled that it would not independently pursue further clinical development of OKI-219 at this time, instead prioritizing its pan-mutant-selective pipeline. That strategic shift, combined with expectations for a longer timeline to key data and regulatory milestones, weighed on sentiment.
Analyst price-target reductions during the period captured this reset, as firms recalibrated estimates for the new pipeline focus and pushed out assumptions for major catalysts. The shares drifted lower through the summer and into October before stabilizing. The recent rebound suggests some investors now view the risk-reward more favorably, though the stock remains well below levels seen earlier in the year.
Key Catalysts to Monitor Going Forward
Looking ahead, investors are likely to focus on OnKure's execution of its next-generation pipeline. Key milestones include the planned IND submissions for OKI-345 and OKI-355 in the first half of 2027 and additional updates from the PIKture-01 trial of OKI-219, with the company planning to report data by the end of 2026. Management's commentary on trial enrollment, safety, and early efficacy signals will be closely watched.
Financial health remains an important consideration for a clinical-stage company with no approved products. Investors should monitor cash balances, projected runway, and any future financing activity. Broader factors, including the market's appetite for pre-revenue biotech names and sector-wide sentiment around oncology drug development, may also influence trading in OKUR. As always, these observations are informational and do not constitute investment advice.
AI Tools in My Research Process
When analyzing names like OKUR, I frequently review AI Trading Bots to understand how quantitative strategies are positioning around clinical-stage biotechs. These tools help highlight automated approaches that have shown consistency across volatile sectors, giving an additional layer of perspective alongside traditional fundamental review. The insights can be particularly useful when weighing near-term technical rebounds against longer-term development timelines.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
OKUR's Stochastic Oscillator soaring into overbought zone
The Stochastic Oscillator for OKUR moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OKUR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
OKUR broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for OKUR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OKUR's RSI Oscillator exited the oversold zone, 7 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on OKUR as a result. In 23 of 29 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for OKUR just turned positive on October 19, 2026. Looking at past instances where OKUR's MACD turned positive, the stock continued to rise in 16 of 16 cases over the following month. The odds of a continued upward trend are 90%.
OKUR moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where OKUR advanced for three days, in 61 of 77 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.674) is normal, around the industry mean (3.498). P/E Ratio (-0.946) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. OKUR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OKUR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What Kinds of ETFs Exist?
Is there such a thing as the “pre-holiday effect?”
What is IRS Publication 527, Residential Rental Property (Including Rental of Vacation Homes)?
5 Factors for Selecting your Trading Style
$1.3 Trillion Chips: 8 AI Winners Retail Traders Should Watch as Semis Race Toward $2 Trillion
General Information
Industry Biotechnology
Advertisement